870 words · Editorial

Tirzepatide vs Semaglutide: What the Head-to-Head Trial Actually Showed

They were finally compared directly, in one randomized trial, at their weight-loss doses. The result was decisive on average — and still not a reason for everyone to switch. Here's the number, and the four situations where the "loser" is the better choice.

Written byGLP1Zoom Editorial, Medical content team · Independent editorial

Medically reviewed byGLP1Zoom Editorial Team, Evidence-based editorial review Reviewed Jul 24, 2026

Published July 24, 2026

Key takeaways

In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20.2% body-weight reduction versus about 13.7% for semaglutide over 72 weeks in roughly 751 adults with obesity and without diabetes.
That is the only randomized head-to-head comparison at obesity doses — earlier tirzepatide-versus-semaglutide claims were cross-trial guesswork with mismatched populations.
Coverage usually decides the real choice before effectiveness does: the best drug you cannot afford loses to the good drug your plan pays for.
Semaglutide now exists as an FDA-approved oral tablet (approved December 2025); tirzepatide remains injection-only.
A 13.7% reduction is a large effect historically — the trial says one drug worked more, not that the other failed.

For years the tirzepatide-versus-semaglutide debate ran on cross-trial guesswork: take the weight loss from one drug's study, compare it to the other drug's separate study, and pretend the populations matched. They didn't, and cross-trial comparisons are how you get confident wrong answers.

Then the two were put in the same trial, randomized, at their obesity doses. So we can stop guessing about the average. Here's what it found — and, just as important, why the average doesn't settle your decision.

The number

In the head-to-head SURMOUNT-5 trial, adults with obesity (and without diabetes) were randomized to tirzepatide or semaglutide and followed for 72 weeks. The result:

Tirzepatide: about −20.2% of body weight
Semaglutide: about −13.7% of body weight
Roughly 751 participants, 72 weeks

That is a real, clinically meaningful gap, in the one design that can support the comparison. On average, at maximum tolerated obesity doses, tirzepatide produced more weight loss than semaglutide. If the only thing you're optimizing is average pounds lost, the trial is not ambiguous.

The two-molecule map — which brand is which, and why "tirzepatide" and "Zepbound" are the same drug — is here if the naming is tripping you up.

Why "more weight loss on average" still isn't the whole decision

An average is a summary of a population. You are one person, and four things routinely override the average:

1. What your insurance covers. The best drug you can't afford loses to the good drug you can. Coverage for these two differs by plan, by indication (diabetes vs weight loss), and by year. Many people's real choice isn't "which is more effective" but "which one my plan will actually pay for," and that can point either way.

2. Side-effect tolerance. Both cause GI effects — nausea, vomiting, constipation, diarrhea — and individuals tolerate them differently. A person who can't tolerate the titration on one molecule and does fine on the other has their answer, regardless of the trial mean. The drug you can stay on beats the drug you quit.

3. Diabetes and other conditions. Tirzepatide acts on two gut-hormone receptors (GIP and GLP-1); semaglutide acts on one (GLP-1). For some people with type 2 diabetes, or with particular tolerability patterns, that difference matters to a clinician in ways a weight-loss average doesn't capture. This is a prescriber conversation, not a spreadsheet one.

4. Form and convenience. Semaglutide now exists as an FDA-approved oral tablet (approved December 2025), not just an injection. For someone who will not or cannot inject, an effective pill they'll actually take beats a slightly-more-effective injection they'll skip. Tirzepatide remains injection-only.

The semaglutide side of that picture — doses, forms, what to expect — is laid out here.

What the trial does not tell you

It's worth being precise about the limits, because this is where confident misreadings start:

It doesn't say semaglutide "doesn't work." A ~14% body-weight reduction is a large effect by any historical standard for a weight-loss drug. The trial says one worked more, not that the other failed.
It doesn't predict your individual result. Trial averages hide wide individual ranges. Some people on semaglutide lost more than some people on tirzepatide. Your outcome depends on dose tolerance, adherence, diet, and biology the trial can't personalize.
It doesn't account for staying power. Both drugs tend to give weight back when stopped. The trial measured people on the drug for 72 weeks; it doesn't tell you what happens in year three, or when a shortage or a price change forces a switch.
It wasn't a diabetes-outcomes trial. This was weight loss in people with obesity and without diabetes. Don't stretch its conclusion onto cardiovascular or glycemic questions it wasn't built to answer.

How to actually decide

A reasonable order of operations:

Start with coverage. Find out what your plan covers, for which indication, and at what out-of-pocket cost. This eliminates half the debate before it starts.
Weigh form. If injection is a dealbreaker, oral semaglutide moves to the front.
Talk conditions with a prescriber. Diabetes, GI history, and other meds can favor one molecule for reasons the weight-loss average doesn't show.
Then, if it's still a tie, use the trial. All else equal, SURMOUNT-5 favors tirzepatide on weight loss. That's the tiebreaker, not the opening move.

The honest summary is that the head-to-head finally gave us a real average, and the average favors tirzepatide — while leaving four common situations where semaglutide is the better individual choice. "Which is more effective on average" and "which is right for you" are different questions, and only one of them was settled by the trial.

Trial figures reflect SURMOUNT-5 as published; individual results vary. Coverage, forms, and prices verified July 2026. This is general information, not medical advice — the choice between these drugs is one to make with a prescriber.

Common questions about Tirzepatide vs Semaglutide: What the Head-to-Head Trial Actually Showed

Is tirzepatide more effective than semaglutide for weight loss?

On average, yes, at obesity doses. The SURMOUNT-5 head-to-head trial randomized adults with obesity and without diabetes and found about 20.2% body-weight reduction with tirzepatide versus about 13.7% with semaglutide over 72 weeks. That average does not settle an individual choice, which also turns on coverage, tolerability, other conditions, and whether you will inject.

When is semaglutide the better choice despite the trial result?

Four situations come up repeatedly: your insurance covers semaglutide and not tirzepatide; you tolerate one molecule's titration and not the other's; a prescriber judges the receptor difference or your other conditions to favor semaglutide; or you will not inject, in which case FDA-approved oral semaglutide beats a slightly more effective injection you skip.

What does SURMOUNT-5 not tell me?

It does not predict your individual result — trial averages hide wide ranges, and some people on semaglutide lost more than some on tirzepatide. It also says nothing about durability after stopping, and it was not a cardiovascular or glycemic outcomes trial, so its conclusion should not be stretched onto questions it was not designed to answer.

Compare tirzepatide and semaglutide providers